

Jonathan French



I am a trained biostatistician who has been working in the pharmaceutical field for approximately 16 years, as both a project-level statistician and a pharmacometrician. My drug development experience has focused primarily in clinical development in neurosciences and oncology. Recently, I have been working to incorporate pharmacometric principles in other public health-related fields.

Given my experience, I have a passionate belief in the need for strong and open working relationships between modeling and simulation scientists and (bio)statisticians. If elected to the ISoP Board of Directors, I will provide a valuable perspective on expanding the base of ISoP membership and strengthening the connections between ISoP and societies more traditionally affiliated with statisticians, such as the American Statistical Association (ASA) and Statisticians in the Pharmaceutical Industry (PSI).

One vehicle for building these relationships will be through the ISoP/ASA Statistics and Pharmacometrics Interest Group (SxP) formed in 2016. I believe that this recently established interest group can provide a springboard for ISoP and ASA to work together to co-sponsor mini-conferences and sessions at annual conferences, collaborate on best-practices, and co-develop training opportunities. I firmly believe there are opportunities for similar collaborative efforts with other societies and organizations.

I have been a member of ISoP since 2011 and have a strong commitment to its success. I am currently serving as the chair of the ISoP Awards committee and as a steering committee member for the ISoP/ASA Statistics and Pharmacometrics Interest Group. Since the inception of the ACoP, I have helped contribute programming content by chairing or organizing multiple scientific sessions. In addition to serving ISoP, I have held elected leadership roles in the Connecticut chapter of the ASA, serving as the President, Vice President, and Secretary.

With your support, I hope to bring my leadership qualities, interests, and experience to the ISoP Board of Directors.